MSC Exosome Sources Compared: Wharton's Jelly vs Amniotic Fluid vs Cord Blood

How source material affects exosome product characteristics, documentation, and regulatory compliance.

The source of MSC exosome material is one of the most important factors in product quality — and one of the least discussed. Not all MSC exosomes are the same, and the tissue source directly affects particle profile, growth factor composition, and regulatory documentation requirements.

Here's how the three major sources compare.

PropertyWharton's Jelly (UC-MSC)Amniotic FluidCord Blood
Cell typeMesenchymal stem/stromal cellsMSC-like + epithelialHematopoietic + MSC
Exosome yieldHigh (bioreactor up to 19.4x)Moderate (native fluid)Moderate-high
Growth factor profileBroad (TGF-b, VEGF, FGF, etc.)Rich (234+ factors)175+ factors
ImmunomodulatoryStrongStrongModerate
Standard processingCulture-expanded (2D or 3D)Minimally manipulatedMinimally manipulated
Regulatory pathway21 CFR 1271 HCT/P21 CFR 1271 HCT/P21 CFR 1271 HCT/P
B&H Bio productN/A (distributed via partners)MatrixAlocyte

Wharton's Jelly (UC-MSC)

Wharton's Jelly is the gelatinous tissue surrounding umbilical cord blood vessels. It's a rich source of young, highly proliferative MSCs with strong immunomodulatory properties. In 3D bioreactor culture, these cells can produce up to 19.4x more exosomes than standard 2D methods. Wharton's Jelly-derived exosomes are prized for their broad growth factor profile and consistent particle sizing.

Amniotic Fluid

Amniotic fluid is collected from full-term, planned C-section donors. It naturally contains a rich cocktail of growth factors, cytokines, and signaling proteins — 234 growth factors in B&H Bio's Matrix product line. Because the fluid is collected without culture expansion (minimally manipulated), the product retains its native composition without laboratory processing beyond sterility and safety testing.

Cord Blood

Umbilical cord blood contains both hematopoietic and mesenchymal populations, processed to preserve naturally occurring soluble proteins and exosomes. B&H Bio's Alocyte combines cord blood plasma with mononuclear cells, delivering ~4 trillion exosomes plus up to 100 million stem cells per dose.

Documentation note: Regardless of source, every batch should ship with independent sterility (USP <71>), endotoxin (USP <85>), and identity testing. B&H Bio uses Eurofins, a CLIA-certified independent lab, for all three on every batch.
View B&H Bio product lines →

Documented, regardless of source.

Request the current-batch Eurofins COA for Matrix or Alocyte.

Request documentation →